Primary study · included by 1 review

Osteogenic growth peptide-loaded 3D-printed PCL scaffolds for the promotion of osteogenesis through the ERK pathway

Q. Wang 2020 · Wang Qing, Yang Xiaojie, Wang Guangfei, et al. · Materials & Design · 2020

Included by

Polycaprolactone Scaffolds for BONE Regeneration in Animal Models of Cranial Defects: A Systematic Review and Meta-Analysis
Non-Cochrane · intervention · 2026 · cited as Wang 2020 · Table 2; reference 38
Outcome this study informsPooled effectEvidenceCertainty
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
QM = 0.163, df = 3, p = 0.983, R2 = 0%16 studiesGRADE not reported
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
QM = 0.01, df = 1, p = 0.922, R2 = 0%16 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
QM = 9.509, df = 3, p = 0.023, R2 = 28.8%20 studiesGRADE not reported
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
Meta-regression beta (difference in MD, %) -0.646 [-15.869, 14.577]16 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
Meta-regression beta (difference in MD, %) 0.853 [-4.49, 6.195]20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
MD 1.68 [0.34, 3.03]18 studies · 194 participantsGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
Meta-regression beta (difference in MD, %) -4.258 [-8.216, -0.3]20 studiesGRADE not reported
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
QM = 0.099, df = 1, p = 0.753, R2 = 0%16 studiesGRADE not reported
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
MD 2.22 [-1.36, 5.8]15 studies · 122 participantsGRADE not reported
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
Meta-regression beta (difference in MD, %) -0.556 [-15.803, 14.691]16 studiesGRADE not reported
Bone regeneration (BV/TV, %) after 2 months (late stage, 3 months)
Polycaprolactone (PCL)-only scaffold vs Empty defect · After 2 months (late; 3 months)
Meta-regression beta (difference in MD, %) 1.527 [-6.989, 10.044]16 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
QM = 0.703, df = 1, p = 0.402, R2 = 0%20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
Meta-regression beta (difference in MD, %) -6.987 [-12.867, -1.108]20 studiesGRADE not reported
Bone regeneration (BV/TV, %) at one month (early stage)
Polycaprolactone (PCL)-only scaffold vs Empty defect · 1 month (early; includes follow-up up to 1 month)
QM = 0.334, df = 1, p = 0.563, R2 = 0%20 studiesGRADE not reported

1 including review in total.